In animal models, interstitial angiotensin II (ang II) and AT1 receptor (AT1R) are key mediators of renal inflammation and fibrosis in progressive chronic nephropathies. We hypothesized that these molecules were overexpressed in patients with progressive glomerulopathies. In this observational retrospective study, we described the expression of ang II and AT1R by immunohistochemistry in kidney biopsies of 7 patients with minimal change disease (MCD) and in 25 patients with progressive glomerulopathies (PGPs). Proteinuria, serum albumin, and serum creatinine were not statistically different between MCD and PGP patients. , respectively, p<0.05), as was the proportion of interstitial fibrosis (11.0±0.7% versus 6.1±1.2%, p<005). In patients with MCD, ang II and AT1R expressions predominate in the tubular compartment (52% and 36% of the positive cells, respectively). In those with PGP, the interstitial expression of ang II and AT1R predominates (58% and 45%, respectively). In conclusion, interstitial expression of ang II and AT1R is increased in patients with progressive glomerulopathies. The relationship of these results and interstitial fibrosis and disease progression in humans warrants further investigations.
Introduction
Angiotensin II (ang II) is recognized as a key mediator in progressive nephropathies leading to chronic renal failure. 1 Owing to its vasoconstrictor properties, it raises systemic blood pressure, a well-known risk factor for progressive renal disease. Ang II may also stimulate mesangial cell contraction and proliferation as well as efferent arteriolar vasoconstriction. Renal arteriolar constriction can induce glomerular hypertension, mesangial expansion with matrix formation, as well as enhanced synthesis of transforming growth factor-β (TGF-β) which has a pivotal role in fibrosis formation. [2] [3] [4] [5] Ang II local actions in renal proximal tubular cells and mesangial glomerular cells are stimuli for TGF-β production while ang II blockade reduces the expression of TGF-β and its urinary excretion. 6 The renal fibrosis that follows those mentioned events is also stimulated by other ang II actions, such as local production of plasminogen activator inhibitor-1, activation of macrophages, enhancement of adrenal production of aldosterone and connective tissue growth factor expression. Some evidence points to a role of ang II in the regulation of inflammatory molecules (cytokines and chemokines) and immunological response in kidney diseases. 1, 7 It is known that most of these inflammatory and fibrogenic effects are mediated by the AT1 receptor (AT1R), 8 and the pharmacological blockade of ang II actions either with angiotensin-converting enzyme inhibitors (ACEIs) or AT1R blockers retards progression of chronic experimental and human nephropathies. [9] [10] [11] In animal models of chronic and progressive nephropathies, such as 5/6 nephrectomy and chronic inhibition of nitric oxide synthesis, 12, 13 ang II and AT1R are overexpressed in renal interstitial cells, particularly in areas of severe renal damage. In an experimental model of salt-sensitive hypertension, Franco et al. 14 showed that blood pressure is negatively correlated with plasma ang II concentrations and positively correlated with intrarenal ang II concentrations. Furthermore, intrarenal ang II concentration was positively correlated with the number Interstitial expression of angiotensin II and AT1 receptor are increased in patients with progressive glomerulopathies of tubulointerstitial ang II positive cells and infiltrating immune cells. As interstitial inflammation and fibrosis are final common events in several distinct forms of chronic progressive nephropathy, the aim of this study was to verify whether the intrarenal renin-angiotensin system (RAS) molecules, ang II and AT1R, were overexpressed in human progressive glomerulonephritis.
Materials and methods
This was a retrospective study that was conducted after the approval of the local Research Ethics Committee (#242/03). Patients with idiopathic glomerular diseases were selected from the renal biopsy data bank of the Nephrology Clinic in the Hospital das Clínicas, University of São Paulo, Brazil. All patients were on medications chosen by the clinical staff including diuretics, antihypertensive and antilipemic drugs except for angiotensin inhibitors (ACEI or AT1 blockers). Inclusion criteria comprised, in addition to proven primary glomerular disease, age in excess of 14 years and serum creatinine concentration (obtained at most 2 months before the kidney biopsy) up to 2.5 mg/dl. We decided to exclude patients with higher serum creatinine levels because when there is already extensive tissue fibrosis without cells, the antibodies cannot react. The 2.5 mg/dl level was an arbitrary choice.
In addition, only kidney biopsies specimens counting at least 10 glomeruli were included. Patients with secondary glomerular diseases (diabetes mellitus, collagen diseases, malignancy, liver diseases, HIV, vasculitis, cryoglobulinemia) were excluded.
We considered a patient to have minimal change disease when he had a pathological description by light and immunofluorescence microscopy compatible with this diagnosis and became free of proteinuria and resumed normal creatinine levels after a short period (1 month) of steroid therapy.
Routine biopsies were performed by the nephrology staff and the glomerulopathy diagnosis was made by pathologists in kidney tissue fixed in Bouin and embedded in paraffin. After that, the percentage of fibrosis in the interstitial area was estimated. To evaluate the extent of renal interstitial expansion, the fraction of renal cortex occupied by interstitial tissue staining positively for extracellular matrix components (%) was quantitatively evaluated in Masson-stained sections by a point-counting technique in 25 consecutive microscopic fields, at a final magnification of ×100 under a 176-point grid.
Ang II and AT1R expressions were studied by immunohistochemistry carried out from paraffinembedded renal sections. Sections were mounted on glass slides coated with 2% gelatin, deparaffinized, and rehydrated using standard techniques. Sections were then exposed to microwave irradiation in citrate buffer to enhance antigen retrieval and preincubated with avidin and biotin solutions to block non-specific binding of these compounds (Bolcking Kit, Vector Labs, Burlingame, CA). After being washed, sections were preincubated with 5% human IgG serum in Tris-buffered saline to prevent non-specific protein binding. For ang II detection a polyclonal antihuman ANG II antibody (Peninsula Lab, San Carlos, CA) was used, whereas AT1R was detected with a polyclonal antihuman AT1R antibody (RDI, Flanders, NJ). Incubation with the primary antibody was carried out overnight in a humidified chamber at 4 o C.
Negative control experiments for all antigens were performed by omitting incubation with the primary antibody. After being washed, the sections were incubated at room temperature with rat-adsorbed biotinylated antirabbit IgG (Vector Labs) for 45 min, then with a streptavidin-biotinalkaline-phosphatase complex (Dako) for an additional 30 min. Finally, sections were treated with a fast-red dye solution, counterstained with hematoxylin and covered with Kaiser's glycerinegelatin (Merk, Darmstadt, Germany). The number of ang II and AT1R positive cells in renal compartments (glomerular, tubular, and interstitial) was evaluated in a blinded manner at ×250 magnification and expressed as cells per square millimeter. For each section, 25 microscopic fields, each corresponding to an area of 0.06 mm 2 , were examined. Data are reported as mean ± standard error of the mean (SEM). Comparisons between groups were performed by Mann-Whitney U-tests and the Spearman correlation was used. The significance limit was a p-value of 0.05. Table 1 . There were 7 patients with minimal change disease (MCD) or a non-progressive glomerulopathy and 25 patients with progressive glomerulopathies (PGPs). Among those with PGP, 9 patients had the diagnosis of focal and segmental glomerulosclerosis (FSGS), 12 of membranous glomerulonephritis (MGN), and 4 of type I membranoproliferative glomerulonephritis (MPGN). Hypertension was diagnosed in 13 patients, and except for #6 and #8, all of the patients had proteinuria above 3 g/day at the time of the biopsy. All patients with FSGS, MGN and MPGN were followed for at least 5 years and none of them became free of proteinuria. We observed, through a Table 2 . The compartmental ang II positive cells distribution is presented in Figure 1 . PGP patients showed the greatest expression in the interstitial compartment (58%) over tubular (30%), glomerular (6%) and vascular (6%), while MCD patients showed the greatest expression in the tubular compartment (52%) compared with the interstitial (20%), glomerular (20%) and vascular (8%). Figure 2 . PGP patients showed the greatest expression in interstitial compartment (45%) over tubular (30%), glomerular (10%) and vascular (15%) while MCD patients showed the greatest expression in the tubular compartment (36%) compared to interstitial (25%) glomerular (14%) and vascular (25%). The illustrations of the immunohistochemistry staining are shown in Figure 3 . The expressions of both molecules in patients with FSGS, MGN and MPGN are presented in Table 4 .
Results

Patient characteristics are presented in
Discussion
It is well known that renal cells (mesangial, tubulointerstitial, glomerular and vascular) may express elements of RAS, such as renin, angiotensinconverting enzyme, angiotensinogen, ang I and II, and angiotensin receptors in experimental animals as well as in humans. 15, 16 Since 1930 the RAS has been associated with hemodynamic events and salt balance, and described as an endocrine system. However, the RAS influences not only systemic and local renal hemodynamics, but also local renal tissue cell infiltration and inflammation. 13, 14, 17, 18 Navar and his group in a series of studies emphasized the importance of the intrarenal RAS [19] [20] [21] with its regulation independent from the systemic RAS. They demonstrated that the interstitial concentrations of ang I and II in rats are 1000 times higher than plasma concentrations 21 and that interstitial fluid ang II concentration was not modified by plasma expansion with Ringer lactate or intravenous infusion of enalaprilat in increasing doses. The bulk of data on the renal and plasma levels of ang II was obtained in rodents. Such a limitation is of particular importance as some authors have suggested that there are considerable differences in the RAS between species. 5 Yet, there are also clinical data supporting the theory of an autonomous regulation of local RAS. 22 In patients with diabetic nephropathy the renal hemodynamic response to the ang II antagonist irbesartan was enhanced substantially, despite the fact that a low-salt diet had provoked a limited increase in PRA in most of the patients, confirming the paradoxical low systemic renin state. We believe that the use of diuretics in our patients which could possibly generate a hypovolemic state would have minor, if any, influence in the expression of local kidney RAS components. None of the patients were taking RAS blockers.
Knowledge about the RAS has evolved in recent years and now we need to deal with regulation of a more complex system. Ang II, the octapeptide angiotensin- (1) (2) (3) (4) (5) (6) (7) (8) , is the most important fragment derived from ang I. There are other biologically active molecules being described, for instance angiotensin-(1-7) and angiotensin-(2-10), derived from ang I. Ang II can be metabolized to other bioactive fragments, such as ang III. Ang II is the preferred ligand for AT1R, but other peptides, such as ang III, can also act through AT1R. The ang II receptor AT2R is also a key receptor for ang III, and some research points to the action of angiotensin-(1-7) also through AT2R. The roles of all of these molecules involved in the RAS in kidney diseases need further investigation. 5, 8 Rabbit anti-angiotensin II (human) antibody shows a high cross reactivity with Val5-ang II (100%) and ang III (100%) and a low reactivity with renin substrate (0.9%) and ang I (0.5%). This cross reactivity data is taken from radioimmunoassay Studies in several animal models of chronic nephropathies suggest a pathogenic role of ang II and AT1R in interstitial inflammation and fibrosis 12, 13, 24 that ends in severe chronic renal failure. In the present study, the expression of ang II in renal tissue was higher in patients with PGP than MCD, although non-significantly. In patients with PGP the predominant expression was interstitial. Mezzano et al., 25 studying 20 patients with idiopathic membranous glomerulonephritis, detected intense expression of ang II in tubular and interstitial cells, compared to biopsies specimens of patients with MCD or specimens of normal portions of renal tissue from tumor-derived nephrectomies. No correlation of tubulointerstitial ang II and fibrosis was detected. The morphometric method was different from that used in our study, as the interstitial and tubular cells were described jointly. We have not found other reports of independent expressions of ang II in tubular and interstitial compartments in patients with primary glomerulopathies.
Regarding the AT1 receptor expression, Mifune et al. 26 studied the distribution of AT1 and AT2 angiotensin receptors in patients with glomerulonephritis (four with MCD, six with IgA nephropathy, eight with membranous glomerulonephritis [MGN] ) and controls (three renal tissues from tumor nephrectomies) by immunohistochemistry, in fresh frozen tissue. Differences between glomerulonephritis patients and controls were not significant. As for AT1R mRNA expression data, Wagner et al. 27 have studied whole kidney and microdissected glomeruli of patients with chronic renal disease. In 37 patients (IgA nephropathy, MGN, MPGN, FSGS/MCD and systemic vasculitis) the expression of AT1R mRNA was lower in patients with glomerulonephritis than in controls (normal renal tissue from tumor nephrectomies). Using a microdissected glomeruli technique, they showed lower expression of AT1R mRNA in patients with glomerulonephritis compared with controls. Although the authors did not study activation of other RAS components, they speculate that the lower expression of AT1R could be a negative feedback in response to probable high intrarenal angiotensin levels. Their methodology was unable to assess the kidney compartments individually. In the present study, observing AT1R protein in the whole specimen of patients' renal biopsies, AT1R expression was higher but nonsignificantly in PGP than in MCD patients. Yet, as for intrarenal distribution, interstitial expression was higher in patients with PGP than in those with MCD. These findings corroborate those reported in experimental models of chronic renal disease. 12, 13 Using similar immunohistochemistry and morphometric techniques, our data with patients were very similar to the results of Zatz and his group in experimental models.
12,17 Gonçalves et al. 12 , using the ablation model of chronic progressive kidney disease in rats, have shown that the increase in ang II and AT1R positive cells was unrelated to vascular tissue, but was related to cortical interstitial area, mostly associated with inflammation. Renal mass reduction did not influence the total AT1R expression in the diseased animal, but promoted a drastic change in its intrarenal distribution, with AT1R expression clearly shifted to the interstitial area. The present study was not designed to test the hypothesis that the local RAS activation would be related to inflamed areas in renal biopsies in patients with glomerulopathies. However, FSGS, MGN and type I MPGN are progressive nephropathies in which interstitial inflammation often occurs and this could be reflected in the higher interstitial fibrosis index, as we found in our patients with these lesions, compared with those with MCD.
Conclusion
The current results in patients with PGP and MCD patients corroborate the experimental data that show enhanced expression of ang II and AT1R in renal interstitium of animals with progressive nephropathies. We believe that the methodology performed here could be useful in other studies in patients concerning involvement of the RAS in glomerular diseases and in their progression. The relationship of these results to interstitial fibrosis and disease progression in humans warrants further investigation. 
